Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation

International Ophthalmology

Volumn 32, Issue 3, 2012, Pages 259-268

  Hufendiek, Katerina ^a   Hufendiek, Karsten ^a   Panagakis, Georgios ^a   Helbig, Horst ^a   Gamulescu, Maria Andreea ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Anti VEGF; Bevacizumab (Avastin ); Functional and morphological outcomes; Ranibizumab (Lucentis ); Retinal angiomatous proliferations (RAP)

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LONG TERM CARE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINAL ANGIOMATOUS PROLIFERATION; RETROSPECTIVE STUDY; TISSUE STRUCTURE; TREATMENT DURATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINA; RETINAL NEOVASCULARIZATION; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84864282400     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-012-9562-0     Document Type: Article

References (26)

1. Yannuzzi LA, Negrao S, Iida T et al (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416-434 (Pubitemid 32971350)
2. Hartnett ME, Weiter JJ, Gardts A, Jalkh AE (1992) Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol 230:11-19
3. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE (1996) Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology 103: 2042-2053 (Pubitemid 27024625)
4. Lafaut BA, Aisenbrey S, Broecke CV, Bartz-Schmidt KU (2000) Clinicopathological correlation of deep retinal vascular anomalous complex in age-related macular degeneration. Br J Ophthalmol 84:1269-1274
5. Kuhn D, Meunier I, Soubrane G, Coscas G (1995) Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol 113:1392-1398
6. Slakter JS, Yannuzzi LA, Schneider U et al (2000) Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 107:742-754 (Pubitemid 30191343)
7. Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G (2005) Treatment of retinal angiomatous proliferation in age-related macular degeneration. Arch Ophthalmol 123:1644-1650
8. Bottoni F, Romano M, Massacesi A, Bergamini F (2006) Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:1528-1533 (Pubitemid 44741267)
9. Freund KB, Klais CM, Eandi CM, Ober MD, Goldberg DE, Sorenson JA, Yannuzzi LA (2006) Sequenced combined intravitreal triamcinolone and indocyanine green angiography- guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 124:487-492
10. Stoffelns BM, Kramann C, Schoepfer K (2008) Laser photocoagulation and photodynamic therapy (PDT) with verteporfin for retinal angiomatous proliferation (RAP) in age-related macular degeneration (AMD). Klin Monbl Augenheilkd 225(5):392-396 German (Pubitemid 352016465)
11. Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA (2005) Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25(6):713-718 (Pubitemid 41254540)
12. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noel A, Munaut C (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186-3193 (Pubitemid 36759791)
13. Hera R, Keramidas M, Peoc'h M, Mouillon M, Romanet JP, Feige JJ (2005) Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol 139(4):589-596
14. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114(10):1868-1875
15. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144(6):850-857
16. Joeres S, Heussen FM, Treziak T, Bopp S, Joussen AM (2007) Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 245(11):1597-1602 (Pubitemid 47491546)
17. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA (2010) Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol 94(6):701-705
18. Wolf A, Kook D, Kreutzer T, Gandorfer A, Haritoglou C, Kampik A, UlbigM(2008) Anti-VEGF treatment for retinal angiomatous proliferation. Ophthalmologe 105(9):845-851 German
19. Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, Klancnik JM, Fisher YL, Cooney MJ, Yannuzzi LA (2007) Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 27:451-457 (Pubitemid 46624285)
20. Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A (2009) Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 247(9): 1165-1171
21. Lai TY, Chan WM, Liu DT, Lam DS (2007) Ranibizumab for retinal angiomatous proliferation in neovascular agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol 245(12):1877-1880 (Pubitemid 350154025)
22. Parodi MB, Iacono P, Menchini F, Sheth S, Polini G, Pittino R, Bandello F (2011) Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol. doi:10.1111/j.1755-3768.2011. 02265.x
23. Jaissle GB, Szurman P, Bartz-Schmidt KU, German Retina Society, German Society of Ophthalmology, German Professional Association of Ophthalmologists (2005) Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 222(5):390-395 (Pubitemid 40825853)
24. Gamulescu MA, Framme C, Sachs H (2007) RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 245(7):1037-1040
25. Holladay JT (2004) Visual acuity measurements. J Cataract Refract Surg 30(2):287-290 (Pubitemid 38366348)
26. Rouvas AA, Papakostas TD, Vavvas D, Vergados I, Moschos MM, Kotsolis A, Ladas ID (2009) Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina 29(4):536-544